Vanda Pharmaceuticals appoints chief commercial officer

Bob Repella joins US biopharmaceutical firm

Vanda Pharmaceuticals has named Bob Repella as senior vice president and chief commercial officer of the US biopharmaceutical firm that specialises in clinical-stage products for CNS disorders.

Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.

Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.

Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.

Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Regulatory

Sleep disorders – tasimelteon

Melatonin can be used to treat sleep disorders, but it has poor bioavailability, and has a half-life in the body of only about 15 minutes
Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

American Chemistry Council's statement to Trump: make chemistry in America again

The Council has released a statement ahead of the President's State of the Union Address, asking for policies that unlock domestic production and address unfair foreign practices
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Regulatory

NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo

Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
Regulatory

CDA-AMC rejects Leqembi reimbursement despite Health Canada approval

After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
Subscribe now